NASDAQ · DRUG
Bright Minds Biosciences Inc.
$56.69+$1.37 (+2.48%)
Bright Minds Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.19% below the high.
Loading market information…
TSX · GUD.TO · CAD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Knight Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Knight Therapeutics Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of CA$0.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Knight Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in Montreal, Canada in 2013, operates globally, with a strong presence across Canada and Latin America. The company's core business revolves around the development, acquisition, in-licensing, out-licensing, promotion, and distribution of a diverse portfolio encompassing pharmaceutical products, consumer health goods, and medical devices. Its extensive product catalog features treatments such as Nerlynx, prescribed for extended adjuvant and metastatic breast cancer; Tafasitamab, used for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib, targeting metastatic cholangiocarcinoma; Trelstar, addressing advanced prostate cancer and pain associated with endometriosis; Vidaza, indicated for myelodysplastic syndrome; Abraxane, for metastatic pancreatic adenocarcinoma; Halaven, for metastatic breast cancer and soft tissue sarcoma; and Lenvima, useful in differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company's offerings further include Ladevina, for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix, for metastatic prostate cancer; Karfib, for relapsed or refractory multiple myeloma; Leprid, for advanced prostate cancer; and Rembre, for chronic myeloid leukemia. For infectious diseases, it provides Ambisome and Cresemba for fungal infections, along with Impavido for leishmaniasis. Other notable products include Exelon, managing mild to moderately severe dementia; Ibsrela, for irritable bowel syndrome with constipation; Salofalk, for ulcerative colitis; Ursofalk, to treat biliary cirrhosis; Imvexxy, for moderate to severe dyspareunia; Bijuva, for moderate to severe vasomotor symptoms linked to menopause in women with intact uteri; Fibridoner, for idiopathic pulmonary fibrosis; Toliscrin DPI, addressing pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2, for severe acute or resistant chronic infections; and Tobradosa Haler, for chronic lung infections. Beyond its product-focused endeavors, Knight Therapeutics Inc. also provides financing to other life science companies and makes strategic investments in life sciences venture capital funds.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | CA$0.02+300.0% vs estimate | CA$88.08M+1.12% vs estimate |
|---|
| Q4 2024 | Mar 19, 2025 | CA$0.11+450.0% vs estimate | CA$96.86M+13.02% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | CA$0.00 | CA$92.26M+5.3% vs estimate |
|---|
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$56.69+$1.37 (+2.48%)
Bright Minds Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.19% below the high.
CA$6.50CA$0.00 (0.0%)
Kneat.com, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
CA$7.28+CA$0.16 (+2.25%)
Verano Holdings Corp’s quoted price sits in the lower half of its reported 52-week range, 45.26% below the high.
CA$7.71+CA$0.18 (+2.39%)
Vitalhub Corp.’s quoted price sits in the lower half of its reported 52-week range, 30.98% below the high.
CA$0.94-CA$0.01 (-1.05%)
Canopy Growth Corporation’s quoted price sits in the lower half of its reported 52-week range, 71.34% below the high.
CA$5.74+CA$0.03 (+0.53%)
Aurora Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.4% below the high.
CA$13.50+CA$0.00 (0.0%)
Cipher Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.34% below the high.
$0.63+$0.02 (+2.82%)
Cresco Labs Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.61% below the high.
